Inter-individual variability in drug response, be it efficacy or safety, is common and likely to
become an increasing problem globally given the growing elderly population requiring …

Proteins are the main targets of most drugs; however, system-wide methods to monitor
protein activity and function are still underused in drug discovery. Novel biochemical …

The role of microglia cells in Alzheimer's disease (AD) is well recognized, however their
molecular and functional diversity remain unclear. Here, we isolated amyloid plaque …

Severe cutaneous adverse reactions (SCARs), which include Stevens–Johnson syndrome
and toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (also …

Peptide antigens bound to molecules encoded by the major histocompatibility complex
(MHC) and presented on the cell surface form the targets of T lymphocytes. This critical arm …

During the past decade, major advances have been made in the accurate diagnosis of
severe cutaneous adverse reactions (SCARs) to drugs, management of their manifestations …

As precision medicine becomes increasingly relevant in healthcare, the field of
pharmacogenomics (PGx) also continues to gain prominence in the clinical setting. Leading …

The Major Histocompatibility Complex (MHC) locus encodes classical MHC class I and MHC
class II molecules and nonclassical MHC-I molecules. The architecture of these molecules is …

Drug hypersensitivity reactions (DHR) are based on distinct mechanisms and are clinically
heterogeneous. Taking into account that also off‐target activities of drugs may lead to …

The immunopeptidome is the set of peptides presented by the major histocompatibility
complex (MHC) molecules, in humans also known as the human leukocyte antigen (HLA) …